To The Moon

Tesla has spent the last several years moving through what, on the surface, can look like a frustrating period of volatility and consolidation. From an Elliott Wave perspective, however, that volatility may be serving a much more important purpose: building a series of nested first and second waves that can eventually produce a powerful third-wave acceleration. Our long-term view on $TSLA remains constructive. The weekly structure suggests that the major advance from the 2023 low is not necessarily the end of the bullish sequence. Instead, we believe Tesla may be developing a nest inside a larger bullish cycle, and that structure can ultimately open the door to the $937 area within the next five years. The important point is that $937 should not be viewed as a conventional fundamental pric

$AbbVie(ABBV)$ is a leading global biopharmaceutical company based in the United States. Ranked among the largest in the industry, it develops treatments across key areas including immunology, cancer, neurology, and aesthetics. Its major products include blockbuster medicines like Humira, Skyrizi, and Rinvoq for autoimmune conditions, cancer therapies like Imbruvica and Venclexta, mental health medication Vraylar, and Botox. The name "AbbVie" originates from a combination of "Abbott," the name of its former parent company, and "vie," which refers to a Latin root meaning 'life.' In a long-term uptrend, but it is currently hitting a strong price ceiling at $260–$262. Momentum is slowing down, which suggests sellers are stepping in and could cause